Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, Danieli R, Deleporte A, Picchia S, Stathopoulos K, Jungels C, Vanderlinden B, Paesmans M, Ameye L, Critchi G, Taraji-Schiltz L, Velghe C, Wimana Z, Bali M, Hendlisz A, Flamen P, Karfis I. Mileva M, et al. Among authors: vanderlinden b. J Nucl Med. 2024 Feb 1;65(2):236-244. doi: 10.2967/jnumed.123.265987. J Nucl Med. 2024. PMID: 38164576 Clinical Trial.
[18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.
Chan DL, Hayes AR, Karfis I, Conner A, Mileva M, Bernard E, Schembri G, Navalkissoor S, Gnanasegaran G, Pavlakis N, Marin C, Vanderlinden B, Flamen P, Roach P, Caplin ME, Toumpanakis C, Bailey DL. Chan DL, et al. Among authors: vanderlinden b. J Nucl Med. 2024 Feb 1;65(2):185-191. doi: 10.2967/jnumed.123.266346. J Nucl Med. 2024. PMID: 38164579 Free PMC article.
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart M, Flamen P. Hendlisz A, et al. Among authors: vanderlinden b. Ann Oncol. 2012 Jul;23(7):1687-93. doi: 10.1093/annonc/mdr554. Epub 2011 Nov 23. Ann Oncol. 2012. PMID: 22112970 Free article.
Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.
Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, Vanderlinden B, Reynaert N, Hendlisz A, Lam M, Deroose CM, Ahmadzadehfar H, Flamen P. Levillain H, et al. Among authors: vanderlinden b. Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2270-2279. doi: 10.1007/s00259-019-04427-z. Epub 2019 Jul 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 31324943
Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score.
Chan DL, Hayes AR, Karfis I, Conner A, Furtado O'Mahony L, Mileva M, Bernard E, Roach P, Marin G, Pavlakis N, Schembri G, Gnanasegaran G, Marin C, Vanderlinden B, Navalkissoor S, Caplin ME, Flamen P, Toumpanakis C, Bailey DL. Chan DL, et al. Among authors: vanderlinden b. Br J Cancer. 2023 Feb;128(4):549-555. doi: 10.1038/s41416-022-02061-5. Epub 2022 Nov 25. Br J Cancer. 2023. PMID: 36434154 Free PMC article.
40 results